Test can predict which patients will benefit from hormonal treatmentsBMJ 2003; 327 doi: http://dx.doi.org/10.1136/bmj.327.7423.1068-a (Published 06 November 2003) Cite this as: BMJ 2003;327:1068
- Susan Mayor
A new test that is based on detecting the activity rather than just the quantity of oestrogen receptors in breast cells has shown promising results, indicating that the test may improve the accuracy of predicting which patients will benefit from hormonal treatments for breast cancer.
Hormonal treatments such as tamoxifen and anastrazole have greatly improved survival from breast cancer, because most breast cancers are stimulated by oestrogen. However, about 30% of patients with breast cancer in which oestrogen receptors are present do not respond to tamoxifen.
Also, a substantial proportion of patients who initially respond to tamoxifen develop resistance. The decision to use these …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial